This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Wall Street Analysts Think NovoCure (NVCR) Could Surge 35.96%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 36% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
New Strong Buy Stocks for August 1st
by Zacks Equity Research
NVCR, KGC, CVNA, KNSA and MU have been added to the Zacks Rank #1 (Strong Buy) List on August 1, 2024.
Wall Street Analysts Believe NovoCure (NVCR) Could Rally 26.39%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of 22.50% and 10.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of 16.28% and 5.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Organon (OGN) Gears Up to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Organon's (OGN) first-quarter results are likely to reflect growth in its biosimilars and established brand franchises with lighter fertility product sales amid foreign exchange headwinds.
What's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect growth in the Wellspect Healthcare business and Orthodontic segment amid foreign exchange headwinds.
What's in Store for Cardinal Health (CAH) in Q3 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) third-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical and Specialty Solutions segment.
Cencora (COR) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Cencora's (COR) second-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.
NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
NovoCure (NVCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medpace (MEDP) Beats Q1 Earnings Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 30.61% and 0.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
NovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NovoCure (NVCR) Soars 12.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
NovoCure (NVCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Does NovoCure (NVCR) Have the Potential to Rally 63.51% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for NovoCure (NVCR) points to a 63.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NovoCure (NVCR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of 15.09% and 0.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in NovoCure (NVCR): Can Its 16.8% Jump Turn into More Strength?
by Zacks Equity Research
NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wall Street Analysts Predict a 105.85% Upside in NovoCure (NVCR): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for NovoCure (NVCR) points to a 105.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
GoodRx Holdings, Inc. (GDRX) Surges 13.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
NovoCure (NVCR) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of 11.54% and 0.83%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Accuray's (ARAY) Treatment Options to be Boosted Post FDA's Nod
by Zacks Equity Research
Accuray's (ARAY) latest regulatory approval is likely to improve breast cancer treatment.
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of -8% and 2.38%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Revvity (RVTY) Q2 Earnings Expected to Decline
by Zacks Equity Research
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NovoCure (NVCR) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of -38.89% and 4.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
NovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of -12.50% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate NovoCure (NVCR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.